TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ConvaTec ( (GB:CTEC) ) has provided an announcement.
ConvaTec Group PLC has announced the repurchase of 3,332,480 ordinary shares as part of its $300 million share buyback program initiated in August 2025. The shares were bought at a volume-weighted average price of 231.60 pence and will be held in treasury, affecting the total voting rights and share calculations for stakeholders.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products and technologies industry, focusing on providing solutions for advanced wound care, ostomy care, continence and critical care, and infusion devices. The company is dedicated to improving the lives of patients and healthcare professionals through innovative products and services.
Average Trading Volume: 7,735,918
Technical Sentiment Signal: Buy
Current Market Cap: £4.7B
For a thorough assessment of CTEC stock, go to TipRanks’ Stock Analysis page.